TY - JOUR
T1 - Role of a small GTPase Cdc42 in aging and age-related diseases
AU - Umbayev, Bauyrzhan
AU - Safarova (Yantsen), Yuliya
AU - Yermekova, Aislu
AU - Nessipbekova, Assem
AU - Syzdykova, Aizhan
AU - Askarova, Sholpan
N1 - Funding Information:
This research was/ funded by the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan (Grant No. AP08856264) and Nazarbayev University (CRP grant No. No. 091019CRP2113, Pure ID 16481096).
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature B.V.
PY - 2023/2
Y1 - 2023/2
N2 - A small GTPase, Cdc42 is evolutionarily one of the most ancient members of the Rho family, which is ubiquitously expressed and involved in a wide range of fundamental cellular functions. The crucial role of Cdc42 includes regulation of the actin cytoskeleton, cell polarity, morphology and migration, endocytosis and exocytosis, cell cycle, and proliferation in many different cell types. Many studies have provided compelling yet contradicting evidence that Cdc42 dysregulation plays an important role in cellular and tissue aging. Furthermore, Cdc42 is a critical factor in the development and progression of aging-related pathologies, such as neurodegenerative and cardiovascular disorders, diabetes type 2, and aging-related disorders of the joints and bones, and the inhibition of the Cdc42 demonstrates potentially significant therapeutic and anti-aging effects in animal models of aging and disease. However, regulation of Cdc42 expression and activity is very complex and depends on many factors, such as the origin and complexity of the tissues, hormonal status, etc. Therefore, this review is focused on current advances in understanding the underlying cellular and molecular mechanisms associated with Cdc42 activity and regulation of senescence in different cell types since they may provide a foundation for novel therapeutic strategies and targeted drugs to reverse the aging process and treat aging-associated disorders.
AB - A small GTPase, Cdc42 is evolutionarily one of the most ancient members of the Rho family, which is ubiquitously expressed and involved in a wide range of fundamental cellular functions. The crucial role of Cdc42 includes regulation of the actin cytoskeleton, cell polarity, morphology and migration, endocytosis and exocytosis, cell cycle, and proliferation in many different cell types. Many studies have provided compelling yet contradicting evidence that Cdc42 dysregulation plays an important role in cellular and tissue aging. Furthermore, Cdc42 is a critical factor in the development and progression of aging-related pathologies, such as neurodegenerative and cardiovascular disorders, diabetes type 2, and aging-related disorders of the joints and bones, and the inhibition of the Cdc42 demonstrates potentially significant therapeutic and anti-aging effects in animal models of aging and disease. However, regulation of Cdc42 expression and activity is very complex and depends on many factors, such as the origin and complexity of the tissues, hormonal status, etc. Therefore, this review is focused on current advances in understanding the underlying cellular and molecular mechanisms associated with Cdc42 activity and regulation of senescence in different cell types since they may provide a foundation for novel therapeutic strategies and targeted drugs to reverse the aging process and treat aging-associated disorders.
KW - Aging
KW - Aging-related diseases
KW - CASIN
KW - Cdc42
KW - Longevity
UR - http://www.scopus.com/inward/record.url?scp=85145606050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145606050&partnerID=8YFLogxK
U2 - 10.1007/s10522-022-10008-9
DO - 10.1007/s10522-022-10008-9
M3 - Review article
C2 - 36598630
AN - SCOPUS:85145606050
SN - 1389-5729
VL - 24
SP - 27
EP - 46
JO - Biogerontology
JF - Biogerontology
IS - 1
ER -
